Cardiovascular Journal of Africa: Vol 35 No 1 (JANUARY/APRIL 2024)

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 35, No 1, January – April 2024 AFRICA 63 HIV-infected pregnant women from Latin America and Caribbean countries. J Infect 2014; 68(6): 572–580. 130. Darmochwal-Kolarz D, Kludka-Sternik M, Tabarkiewicz J, Kolarz B, Rolinski J, Leszczynska-Gorzelak B, et al. The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia. J Repro Immunol 2012; 93(2): 75–81. 131. Campillo-Gimenez L, Cumont M-C, Fay M, Kared H, Monceaux V, Diop O, et al. AIDS progression is associated with the emergence of il-17–producing cells early after simian immunodeficiency virus infection. J Immunol 2010; 184(2): 984–992. 132. Terness P, Kallikourdis M, Betz AG, Rabinovich GA, Saito S, Clark DA. Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatory T cells. Am J Repro Immunol 2007; 58(3): 238–254. 133. Sasaki Y, Darmochwal‐Kolarz D, Suzuki D, Sakai M, Ito M, Shima T, et al. Proportion of peripheral blood and decidual CD4+ CD25bright regulatory T cells in pre‐eclampsia. Clin Exp Immunol 2007; 149(1): 139–145. 134. Andersson J, Boasso A, Nilsson J, Zhang R, Shire NJ, Lindback S, et al. Cutting edge: the prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol 2005; 174(6): 3143–3147. 135. Pozo-Balado MM, Martínez-Bonet M, Rosado I, Ruiz-Mateos E, Méndez-Lagares G, Rodríguez-Méndez MM, et al. Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects. J Infect Dis 2014; 210(6): 890–898. 136. Toribio M, Neilan TG, Zanni MV. Heart failure among people with HIV: evolving risks, mechanisms, and preventive considerations. Curr HIV/AIDS Rep 2019; 16(5): 371–380. 137. Erqou S, Lodebo BT, Masri A, Altibi AM, Echouffo-Tcheugui JB, Dzudie A, et al. Cardiac dysfunction among people living with HIV: a systematic review and meta-analysis. J Am Coll Cardiol Heart Fail 2019; 7(2): 98–108. 138. Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries: results of the sub-Saharan Africa survey of heart failure. Arch Int Med 2012; 172(18): 1386–1394. 139. Sliwa K, Davison BA, Mayosi BM, Damasceno A, Sani M, Ogah OS, et al. Readmission and death after an acute heart failure event: predictors and outcomes in sub-Saharan Africa: results from the THESUS-HF registry. Eur Heart J 2013; 34(40): 3151–3159. 140. Toribio M, Neilan TG, Awadalla M, Stone LA, Rokicki A, Rivard C, et al. Intramyocardial triglycerides among women with vs without HIV: hormonal correlates and functional consequences. J Clin Endocrin Metab 2019; 104(12): 6090–6100. 141. Hunt PW. Very Early ART and Persistent Inflammation in Treated HIV. USA: Oxford University Press, 2017. 142. Stanley TL, Grinspoon SK. GH/GHRH axis in HIV lipodystrophy. Pituitary 2009; 12(2): 143–152. 143. Lo J, Abbara S, Rocha-Filho JA, Shturman L, Wei J, Grinspoon SK. Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters. AIDS 2010; 24(13): 2127. 144. Brown TT, Glesby MJ. Management of the metabolic effects of HIV and HIV drugs. Nature Rev Endocrin 2012; 8(1): 11. 145. Nduka CU, Uthman OA, Kimani PK, Stranges S. Body fat changes in people living with HIV on antiretroviral therapy. AIDS Rev 2016; 18(4): 198–211. 146. Freiberg M, Chang C, Oursler K, Gottdiener J, Gottlieb S, Warner A, et al. (eds). The risk of and survival with preserved vs. reduced ejection fraction heart failure by HIV status. 20th conference on retroviruses and opportunistic infections, 2013. 147. Sereti I, Krebs SJ, Phanuphak N, Fletcher JL, Slike B, Pinyakorn S, et al. Initiation of antiretroviral therapy in early HIV infection reduces but does not abrogate chronic residual inflammation. Clin Infect Dis 2016: 683. 148. Hijmans JG, Stockelman KA, Garcia V, Levy MaV, Brewster LM, Bammert TD, et al. Circulating microparticles are elevated in treated HIV‐1 infection and are deleterious to endothelial cell function. J Am Heart Assoc 2019; 8(4): e011134. 149. Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N, et al. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res 2012; 93(4): 633–644. 150. Lovren F, Verma S. Evolving role of microparticles in the pathophysiology of endothelial dysfunction. Clin Chem 2013; 59(8): 1166–1174. 151. Zanni MV, Awadalla M, Toribio M, Robinson J, Stone LA, Cagliero D, et al. Immune correlates of diffuse myocardial fibrosis and diastolic dysfunction among aging women with human immunodeficiency virus. J Infect Dis 2020; 221(8): 1315–1320. 152. Williams DW, Byrd D, Rubin LH, Anastos K, Morgello S, Berman JW. CCR2 on CD14+ CD16+ monocytes is a biomarker of HIV-associated neurocognitive disorders. Neurol Neuroimmun Neuroinflam 2014; 1(3). 153. Sliwa K, Carrington MJ, Becker A, Thienemann F, Ntsekhe M, Stewart S. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur Heart J 2012; 33(7): 866–874. 154. Alvi RM, Afshar M, Neilan AM, Tariq N, Hassan M, Gerber J, et al. Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center. Am Heart J 2019; 210: 39–48. 155. Freiberg MS, Chang C-CH, Skanderson M, Patterson OV, DuVall SL, Brandt CA, et al. Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the Veterans Aging Cohort Study. J Am Med Assoc Cardiol 2017; 2(5): 536-546. 156. Janjua SA, Triant VA, Addison D, Szilveszter B, Regan S, Staziaki PV, et al. HIV infection and heart failure outcomes in women. J Am Coll Cardiol 2017; 69(1): 107–108. 157. Cerrato E, D’Ascenzo F, Biondi-Zoccai G, Calcagno A, Frea S, Grosso Marra W, et al. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. Eur Heart J 2013; 34(19): 1432–1436.

RkJQdWJsaXNoZXIy NDIzNzc=